Biotech Values

[steveporsche]

Speaking of ELN

Related:Elan Corp. plc
DUBLIN, Ireland & SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) announced today that it is realigning some of its functions to direct additional investment towards its innovative pipeline. The realignment will result in the elimination of a number of positions and additional refinement to Elan’s commercial activities in Tysabri for Crohn’s disease. Elan has also decided to close its offices in New York and Tokyo during the first quarter of 2009.

Elan CEO Kelly Martin said that for the past several months the company has been assessing several options to ensure sufficient resources are directed toward its most promising research and development opportunities. “We continually evaluate our pipeline, product portfolio, and company structure with a goal of maintaining our flexibility and ability to invest in the most valuable product opportunities for patients while driving value for our shareholders,” Martin said.

Elan President Carlos V. Paya, MD, PhD, said that Elan will shift its effort from what is a traditional sales commercial model to a model based on clinical support and education. “Going forward,” Dr. Paya said, “we will continue providing the appropriate clinical information and scientific data to support the key gastroenterologist relationships we have established in the United States. Elan continues to believe Tysabri is an important therapeutic option for patients with moderately to severely active Crohn’s disease for whom conventional CD therapies and anti-TNFs are not viable.”

http://finance.yahoo.com/news/Elan-Announces-Resource-bw-13814157.html